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Summary
Background:  To  systematically  assess  the  current  clinical  evidence  of  Zhigancao  (ZGC)  Decoction
for premature  ventricular  contractions  (PVCs).
Search  strategy:  PubMed,  the  Cochrane  Center  Controlled  Trials  Register,  EMBASE,  Chinese
National Knowledge  Infrastructure,  Chinese  Scientiﬁc  Journal  Database,  and  Wanfang  Med
Online Database  were  searched  until  June  2014.  We  included  randomized  clinical  trials  testing
ZGC Decoction  against  anti-arrhythmic  drugs,  ZGC  Decoction  combined  with  anti-arrhythmic
drugs versus  anti-arrhythmic  drugs  alone.  Study  selection,  data  extraction,  quality  assessment,
and data  analyses  were  conducted  according  to  the  Cochrane  standards.  A  meta-analysis  of
improving  total  effects  and  reducing  number  of  ventricular  premature  beats  was  performed  to
evaluate the  effects  of  ZGC  Decoction  on  PVCs.
Results:  A  total  of  25  studies  (involving  2441  patients)  were  included.  The  methodological  qual-
ity of  the  included  trials  was  evaluated  as  generally  low.  The  results  of  the  meta-analysis  showed
that ZGC  Decoction  combined  with  anti-arrhythmic  drugs  had  signiﬁcant  effect  on  improving
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total  effects  (RR:  1.30  [1.22,  1.38];  P  <  0.00001)  and  relieving  number  of  ventricular  premature
beats (MD:  −6.66  [−12.94,  −0.37];  P  =  0.04)  compared  with  anti-arrhythmic  drugs  alone.  Our
review showed  that  ZGC  Decoction  was  more  effective  in  improving  total  effects  (RR:  1.22  [1.08,
1.37]; P  =  0.0009),  compared  with  anti-arrhythmic  drugs  alone.  13  trials  reported  adverse  events,
while the  others  did  not  mention  them,  indicating  that  the  safety  of  ZGC  Decoction  remains
uncertain.
Conclusions:  ZGC  Decoction  appears  to  have  beneﬁcial  effects  on  improvement  of  total  effects,
reduction of  number  of  ventricular  premature  beats  in  participants  with  PVCs.  However,  further
thorough  investigation,  large-scale,  proper  study  designed,  randomized  trials  of  ZGC  Decoction
for PVCs  will  be  required  to  justify  the  effects  reported.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
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sible  number  of  trials  of  ZGC  Decoction  for  hypertension,
becuase  ZGC  Decoction  is  mainly  used  and  researched
in  China.  The  following  search  terms  were  used  individ-BY-NC-ND  license  (http://cre
Introduction
Premature  ventricular  contractions  (PVCs)  are  the  most
common  arrhythmias  observed,  and  the  majority  of  patients
who  have  this  arrhythmia  have  no  structural  heart  disease.1
Observational  studies  have  documented  PVCs  in  about  6%
of  the  general  population.2,3 They  rarely  affect  prognosis
or  management.  However,  they  might  produce  bothersome
symptoms  and,  in  select  individuals  with  a  high  PVC  burden,
they  might  contribute  to  left  ventricular  (LV)  dysfunction
and  dilation,  and  hemodynamic  deterioration.4—7 Frequent
PVCs  cause  severe  symptoms  such  as  dyspnea,  chest  pain,
dizziness  and  palpitations  and  may  even  be  incapacitating
in  some  patients.8,9 And  not  only  that,  more  and  more  pre-
vious  studies  have  shown  that  frequent  PVCs  in  patients
with  established  heart  disease  are  associated  with  increased
risk  of  cardiac  mortality.10—12 Recent  meta-analysis  of  pre-
mature  ventricular  complexes  demonstrated13 that  frequent
PVCs  are  associated  with  a  substantial  increase  in  the  risk
for  sudden  cardiac  death  and  total  cardiac  death  ﬁndings
from  observational  studies  in  general  populations.  Thus,
the  prevention  and  management  of  PVCs  are  major  pub-
lic  health  challenges.  In  recent  decades,  different  classes
of  anti-arrhythmic  were  developed  and  tested  in  a  variety
of  settings  and  among  different  patients.  Clinical  research
ﬁnds  the  medical  therapy  of    blockers  or  class  I  or  III
anti-arrhythmic  agents  are  effective  and  recommended  to
improve  symptoms.  However,  the  long-term  use  of  west-
ern  medicine  will  produce  some  side  effects,  even  produce
resistance  and  affect  therapeutic  efﬁcacy,  even  with  the
advance  of  catheter  ablation  for  ventricular  tachycardia,
anti-arrhythmic  drugs  remain  an  important  tool  for  treat-
ing  arrhythmias.14 Therefore,  seeking  for  a  new  effective
anti-arrhythmic  method  is  an  important  subject  of  PVCs
treatment.
Complementary  and  alternative  (CAM)  therapy  has
become  popular  among  patients  with  chronic  illnesses
because  of  its  widespread  use.15,16 Traditional  Chinese
Medicine  (TCM),  as  a  complementary  therapeutic  regi-
men,  has  broad  clinical  prospects  due  to  its  advantages
with  respect  to  multiple  targets,  signiﬁcant  efﬁcacy  and
safety.17,18 Zhigancao  (ZGC)  Decoction  is  one  kind  of  tra-
ditional  Chinese  herbal  medicine,  which  has  the  function
beneﬁting  qi  and  nourishing  yin,  tonifying  yang,  nourishing
blood  and  reducing  the  palpitation.  It  is  a  representative
formula  to  treat  almost  any  kind  of  arrhythmia  in  Treatise
on  Febrile  Diseases  (Shang  Han  Lun  in  Chinese)  written  by
u
v
‘
‘commons.org/licenses/by-nc-nd/4.0/).
hang  Zhongjing  in  the  Eastern  Han  Dynasty  (25—280  AD),
ontaining  nine  commonly  used  herbs  (Radix  glycyrrhizae
reparata,  Ginger, Cassia  Twig, Ginseng,  dried  rehmannia,
onkey-hide  gelatin, Radix  Ophiopogonis, Fructus  Cannabis,
ructus  Ziziphi  Jujubae).  Several  clinical  trials  have  shown
hat  ZGC  Decoction  might  have  the  therapeutic  effect  of
mproving  symptoms  of  heart  palpitations,  shortness  of
reath,  insomnia,  fatigue  in  patients  with  PVCs.19 Mecha-
ism  of  anti-arrhythmic  effect  is  mainly  blockade  effect  of
ifferent  ion  channels  to  shorten  ventricular  muscle  cells
PD  (action  potential  duration)  and  increase  self-discipline.
nd,  until  now,  a  large  number  of  randomized  controlled  tri-
ls  (RCTs)  and  case  series  have  been  published  but  have  not
een  evaluated  according  to  the  PRISMA  systematic  review
tandard.  Understanding  the  effect  of  ZGC  Decoction  on
VCs  could  be  valuable  for  the  management  of  PVCs.  There-
ore,  this  study  aims  to  assess  the  efﬁcacy  and  safety  of  ZGC
ecoctio  alone  or  combined  with  anti-arrhythmic  drugs  for
VCs.
ethods
he  supporting  PRISMA  checklist  is  available  as  supporting
nformation;  see  Checklist  1.
atabase  and  search  strategies
hree  authors  (W.  Liu,  X.  J.  Xiong  and  F.  Y.  Chu)  searched
ll  the  clinical  trials  about  ZGC  Decoction  for  treatment
f  PVCs  in  six  electronic  databases,  including  PubMed,  the
ochrane  Center  Controlled  Trials  Register  (2014),  EMBASE
1980—2014),  Chinese  National  Knowledge  Infrastructure
CNKI,  1979-June  2014),  Chinese  Scientiﬁc  Journal  Database
VIP,  1989—June  2014),  and  Wanfang  Med  Online  Database
WMOD,  1998—June  2014)  from  their  inception  to  31  June,
014.  We  also  searched  the  reference  list  of  retrieved
apers.  We  systematically  searched  for  studies  on  ZGC
ecoction  published  without  language  restriction.  Databases
n  Chinese  were  searched  to  retrieve  the  maximum  pos-ally  or  combined:  ‘‘Zhigancao  Decoction’’,  ‘‘premature
entricular  contractions’’,  ‘‘premature  ventricular  beats’’,
‘Randomized  Controlled  Trial’’,  ‘‘controlled  clinical  trial’’,
‘randomly’’,  ‘‘trial’’,  ‘‘randomised’’  and  ‘‘randomized’’.
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he  bibliographies  of  included  studies  were  searched  for
dditional  references.
tudy  selection
wo  reviewers  (R.  Yuan  and  B.  Feng)  independently  screened
he  titles,  abstracts,  and  key  words  of  each  searched  article
or  potentially  eligible  studies.  The  randomized  controlled
rials  that  evaluated  the  effectiveness  of  ZGC  Decoction
or  PVCs  were  included:  (a)  participants  were  suffering
rom  and  being  treated  for  premature  ventricular  contrac-
ions;  (b)  the  study  was  claimed  to  be  an  RCT;  (c)  the
tudy  compared  premature  ventricular  contractions  with
nti-arrhythmic  drugs  in  efﬁcacy;  (d)  assessed  one  or  more
elevant  clinical  outcome  measure  such  as  total  effect  for
VCs  and  number  of  ventricular  premature  beat.  Duplicated
r  redundant  studies  were  excluded.  If  there  were  discrep-
ncies  in  the  process  of  selection,  whether  to  include  or
xclude  a  study  was  resolved  by  a  third  author  (H.X.  Liu).
nclusion  criteria
e  included  randomized  controlled  trials  that  compared
GC  Decoction  with  anti-arrhythmic  drugs  in  patients  with
VCs.  The  eligible  comparisons  include  (i)  ZGC  Decoction
ersus  any  anti-arrhythmic  drugs;  (ii)  ZGC  Decoction  plus  any
nti-arrhythmic  drugs  versus  anti-arrhythmic  drugs  alone.
here  was  no  restrictions  on  language,  population  character-
stics,  and  publication  type.  The  primary  outcome  measure
as  total  effect  for  PVCs  and  number  of  ventricular  prema-
ure  beat,  and  the  secondary  outcome  measure  was  adverse
vents.
The  clinical  standards  of  PVCs  by  ‘‘Clinical  research
uideline  of  medicine  for  cardiovascular  system  by  Min-
stry  of  Public  Health  (1998)’’20 were  described  as  follows.
n  the  aspect  of  effective  ECG  improvements,  marked
ffective  result:  ventricular  premature  contraction  dimin-
shed  or  decreased  more  than  90%  in  24  h  of  ambulatory
CG  monitoring  (Holter);  effective  result:  ventricular  pre-
ature  contraction  diminished  or  decreased  more  than
0%  in  24-h  Holter;  ineffective  result:  ventricular  prema-
ure  contraction  diminished  or  decreased  less  than  50%
n  24-h  Holter.  In  the  aspect  of  effective  symptomatic
mprovements,  marked  effective  result:  Chest  distress  and
alpitation  symptoms  disappeared  or  improved;  effective
esult:  Chest  distress  and  palpitation  symptoms  partially  dis-
ppeared  or  improved;  ineffective  result:  Chest  distress  and
alpitation  symptoms  had  no  improvement  or  aggravated.
ethodological  quality  assessment
he  qualities  of  included  RCTs  were  assessed  by  six  speciﬁc
omains,  including  random  sequence  generation,  alloca-
ion  concealment,  blinding  of  participants  and  personnel,
linding  of  outcome  data,  incomplete  outcome  data,  and
elective  reporting.  The  methodological  quality  of  trials  was
ssessed  independently  using  criteria  from  the  Cochrane
andbook  for  Systematic  Review  of  Interventions,  Version
.1.0  (W.  Liu,  F.  Y.  Chu).21 The  quality  of  all  the  included  tri-
ls  was  categorized  to  low/unclear/high  risk  of  bias.  Then
m
s
H
pW.  Liu  et  al.
rials  were  categorized  into  three  levels:  low  risk  of  bias  (all
he  items  were  in  low  risk  of  bias),  high  risk  of  bias  (at  least
ne  item  was  in  high  risk  of  bias),  unclear  risk  of  bias  (at
east  one  item  was  in  unclear).
ata  analysis
e  performed  meta-analyses  using  RevMan  5.1  software
rovided  by  Cochrane  Collaboration  for  data  analyses.21
ichotomous  data  were  expressed  as  relative  risk  (RR)  and
ontinuous  outcomes  were  presented  as  weighted  mean  dif-
erence  (WMD),  while  95%  conﬁdence  intervals  (CI)  were
alculated  for  both.  Meta-analysis  was  performed  if  the
ntervention,  control,  and  outcomes  were  the  same  or
imilar.  The  statistical  heterogeneity  was  presented  as  sig-
iﬁcant  when  I  square  (I2)  value  exceeded  50%.  In  the
bsence  of  signiﬁcant  heterogeneity,  we  pooled  data  using
xed  effects  model  (I2 <  50%);  otherwise  we  used  random
ffects  model  (I2 >  50%).
isk  of  bias  across  studies
 simple  analysis  of  funnel  plots  provides  a  useful  test  for
he  likely  presence  of  bias  in  meta-analyses.  Begg’s  test  and
gger’s  test  were  used  to  test  the  statistical  signiﬁcance  of
he  publication  bias.
esults
escription  of  included  trials
 total  of  515  studies  were  identiﬁed  through  searching  6
lectronic  databases.  The  majority  were  excluded  because
uplicates  were  removed  and  some  included  irrelevant  titles
nd  abstracts.  Only  176  studies  were  retrieved.  After  read-
ng  the  titles  and  abstracts,  only  51  studies  remained.  26
rticles  were  excluded  with  reasons  listed  as  the  follow-
ng:  20  trials  did  not  use  the  criteria  of  total  effect  for  PVC
nd  numbers  of  ventricular  premature  contractions  as  the
utcome  measure,  2  trials  have  no  control  group,  3  trials
ncluded  Chinese  herbal  formula  as  the  control  group  and  1
rial  had  no  data  for  extraction.  In  the  end,  25  RCTs  were
ncluded,  and  all  trials  had  been  conducted  and  published  in
hina.  A  ﬂow  chart  depicted  the  search  process  and  study
election  (as  shown  in  Fig.  1).
The  25  RCTs,22—46 which  involved  a  total  number  of  2441
atients  with  PVCs,  with  the  average  number  of  98  per  trial,
anging  from  38  to  212,  were  published  between  1999  and
014.  There  was  a  wide  variation  in  the  age  of  subjects
14—81  years).  5  trials27,29,39—41 study  PVCs  with  coronary
eart  disease,  and  11  trials22—28,38,43—45 enrolled  patients
ith  frequent  premature  ventricular  complexes.  25  trials
peciﬁed  5  diagnostic  criteria:  Three  trials22,25,28 demon-
trated  that  patients  with  frequent  PVCs  diagnosis  were
ore  than  60/h.  Two  trials38,44 of  frequent  PVCs  diagnosis
ere  more  than  30/h.  Two  trials23,45 used  diagnosis  crite-
ia  of  more  than  5/min.  One  trial24 used  diagnosis  criteria
f  more  than  300/h.  One  trial26 used  diagnosis  criteria  of
ore  than  7/min,  and  the  rest  trials29—37,39—42,46 only  demon-
trated  patients  with  PVCs  by  electrocardiogram  and  24-h
olter.  Among  the  included  clinical  trials,  12  trials22—33 com-
ared  ZGC  Decoction  versus  anti-arrhythmic  drugs  alone,
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Table  1  Characteristics  of  included  studies.
Study  ID Sample
(M/F)
Age  (years)  Classiﬁcation  Clinical  standard  Intervention  Control  Course
(week)
Outcome
measure
Bai22 72
T:  17/19;  C:
21/15
T:  12—78
C:  14—71
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>60/h)
24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Amiodarone
(200  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;
Cheng23 76
T:  23/15;  C:
21/17
T:  65.8  ±  6.2
C:
65.8  ±  4.2
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>5/min)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Propafenone
(150  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;  Adverse
event
Yang24 65
T:  12/21;  C:
11/21
T:  18—48
C:  18—50
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>300/h)
Clinical  research
guideline  of  medicine
for cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)
Metoprolol
tartrate
(25  mg,  bid,
p.o.)
3  Total  effect  for
PVCs;
Yang25 72
T:  17/19;  C:
21/15
T:  12—78
C:  14—71
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>60/h)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Amiodarone
(200  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;
Sun26 172
T:  101;
C: 71
T/C  not
reported
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>7/min)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Amiodarone
(200  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;
Adverse  event
Ye et  al.27 50
T:  14/10;  C:
11/14
T:  59—75
C:  58—73
Unclear  24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Amiodarone
(200  mg,
tid,  p.o.);
Mexiletine
Hydrochlo-
ride  Tablets
(200  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;
Number  of
Ventricular
Premature  Beat
104
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Table  1  (Continued)
Study  ID  Sample
(M/F)
Age  (years)  Classiﬁcation  Clinical  standard  Intervention  Control  Course
(week)
Outcome
measure
Xing  et  al.28 90
T:18/28;
C:15/29
T:
39.2  ±  6.25
C:
38.79  ±  6.31
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>60/h)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Moracizine
(200  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;  Adverse
event
Zhang29 120
T:  60;  C:60
T/C  not
reported
Unclear  Clinical  research
guideline  of  medicine
for  cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)
Propafenone
(150  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;  Adverse
event
Luo30 55
T:  14/16;  C:
11/14
T:  21—65
C: 19—66
Lown  classiﬁcation
(Classes  3,
frequent
multifocal
ventricular
premature  beat)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Amiodarone
(200  mg,
bid,  p.o.)
4  Total  effect  for
PVCs;  Adverse
event
Chen31 164
T:  36/46;  C:
36/46
T:
39.2  ±  6.25
C:
38.79  ±  6.31
Unclear  24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)
Metoprolol
(12.5—25  mg,
bid,  p.o.)
4  Total  effect  for
PVCs;
Zhou and  Zhang32 68
T:  20/14;  C:
21/13
T:  32—78
C: 34—76
Lown  classiﬁcation
(Classes  II-IV)
Clinical  research
guideline  of  medicine
for  cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)
Mexiletine
Hydrochlo-
ride  Tablets;
Metoprolol
3  Total  effect  for
PVCs;
Niu et  al.33 76
T:  18/22;  C:
17/19
T:  45
C: 46
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>300/h)
Clinical  research
guideline  of  medicine
for  cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)
Propafenone  4  Total  effect  for
PVCs;
Adverse  event
Li et  al.34 116
T:  34/25;  C:
31/26
T:  57.5
C: 57
Unclear  Clinical  research
guideline  of  medicine
for  cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Propafenone
(75—150  mg,
bid  or  tid,
p.o.)
2  Total  effect  for
PVCs;
Zhigancao
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Liang35 92
T/C  not
reported
T/C  not
reported
Unclear  Clinical  research
guideline  of  medicine
for cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Propafenone
(150  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;
Number  of
Ventricular
Premature  Beat
Bi and  Kang36 95
T:  37/13;  C:
32/13
T:  43  to  75
C: 45  to  76
Unclear  Clinical  research
guideline  of  medicine
for cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Propafenone
(50  mg,  bid
or  tid,  p.o.)
3  Total  effect  for
PVCs;
Zhang et  al.37 96
T:  23/25;  C:
24/24
T:
56.3  ±  13.2
C:
54.8  ±  11.9
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>30/h)
24  h  Holter Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Metoprolol
(12.5—25  mg,
bid,  p.o.)
4  Total  effect  for
PVCs;  Adverse
event
Wang38 75
T:  21/19;  C:
16/19
T:  33.1
C: 35.5
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>30/h)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Mexiletine
Hydrochlo-
ride  Tablets
(150  mg,
tid,  p.o.)
3  Total  effect  for
PVCs;
Guo39 124
T:  36/26;  C:
37/25
T:  54.8  ±  6.4
C:
55.2  ±  6.7
Lown  classiﬁcation
(Classes  II-IVA)
24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Mexiletine
Hydrochlo-
ride  Tablets
(150  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;  Number
of  Ventricular
Premature
Beat;  Adverse
event
Fan and  Guo40 68
T:  18/16;  C:
17/17
T:
53.43  ±  4.78
C:
52.49  ±  4.83
Lown  classiﬁcation
(Classes  II-IVA)
24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Mexiletine
Hydrochlo-
ride  Tablets
(150  mg,
tid,  p.o.)
4  Total  effect  for
PVCs;  Number
of  Ventricular
Premature
Beat;  Adverse
event
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Table  1  (Continued)
Study  ID  Sample
(M/F)
Age  (years)  Classiﬁcation  Clinical  standard  Intervention  Control  Course
(week)
Outcome
measure
Li  and  Zhou41 212
T:  87/63;  C:
38/24
T:  49—70
C: 51—70
Unclear  Etiology,  severity  and
of  curative  standard
of  common
arrhythmia  (1979)
Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Propafenone
(100—200  mg,
tid, p.o.)
8  Total  effect  for
PVCs;  Number
of  Ventricular
Premature
Beat;  Adverse
event
Wang and  Zhao42 96
T:  26/24;  C:
25/21
T:  12—70
C: 14—72
Unclear  24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Mexiletine
Hydrochlo-
ride  Tablets
(150  mg,
tid,  p.o.)
6  Total  effect  for
PVCs;
Ning43 90
T:  24/21;  C:
23/22
T:  16—76
C: 17—73
Unclear  24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Amiodarone
(200  mg,
tid,  p.o.)
3  Total  effect  for
PVCs;  Adverse
event
Wang et  al.44 60
T:  19/11;  C:
17/13
T:
50.50  ±  56.5
C:
50.18  ±  5.57
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>30/h)
Unclear  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Amiodarone
(200  mg,
tid,  p.o.)
12  Total  effect  for
PVCs;
Wang45 75
T:  28/17;  C:
18/12
T:  36—65
C: 39—66
Lown  classiﬁcation
(Classes  II,
Number  of
Ventricular
Premature  Beat
>5/min)
Clinical  research
guideline  of  medicine
for cardiovascular
system  by  Ministry  of
Public  Health  (1998)
Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Metoprolol
tartrate
(12.5  mg,
bid,  p.o.)
4  Total  effect  for
PVCs;  Adverse
event
Yuan and  Wang46 162
T:  47/34;  C:
46/35
T:50.50  ±  56.5
C:
50.18  ±  5.57
Unclear  24  h  Holter  Modiﬁed  ZGC
Decoction  (1
dose/d#)  +  C
Esmolol
(12.5  mg,
qd,  I.V.)
4  Total  effect  for
PVCs;  Adverse
event
T, intervention group; C, control group; PVCs, premature ventricular contractions; C, control.
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Table  2  Compositions  of  ZGC  Decoction  in  the  included  trials.
Study  ID  Formula  Composition  of  formula
Bai22 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)30  g;  Donkey-hide  gelatin  (e
jiao)10 g;  Radix  Ophiopogonis  (Mai  dong)  20  g;  Cassia  Twig  (Gui  zhi)15  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)15  g;  Fructus  Cannabis(Huo  maren)15  g;  Ginger  (Sheng
jiang)10  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g
Cheng23 ZGC  Decoction Radix  glycyrrhizae  preparata  (Zhi  gancao)60  g;  Donkey-hide  gelatin  (e
jiao)6 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig(Gui  zhi)10  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)50  g;  Fructus  Cannabis(Huo  maren)10  g;  Ginger  (Sheng
jiang)10  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g
Yang24 Modiﬁed  ZGC  Decoction  Radix  Bupleuri  (Chai  hu)15  g;  Radix  Paeoniae  Alba  (Bai  shao)12  g;  Bitter
Orange (Zhi  ke)12  g;  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;
Radix  curcumae  (Yu  jin)15  g;  Tuber  Fleeceﬂower  Stem  (Ye  jiaoteng)15  g;
Polygala  tenuifolia  (Yuan  zhi)9  g;  Pinellia  ternata  (Ban  xia)9  g;  Rhizoma
Cyperi  (Xiang  fu)9  g;  Ligusticum  wallichii  (Chuan  xiong)9  g;  rhizoma
acori graminei  (Shi  changpu)12  g
Yang25 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)30  g;  Donkey-hide  gelatin  (e
jiao)10 g;  Radix  Ophiopogonis  (Mai  dong)  20  g;  Cassia  Twig(Gui  zhi)15  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)15  g;  Fructus  Cannabis  (Huo  maren)15  g;  Ginger  (Sheng
jiang)10  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g
Sun26 ZGC  Decoction Radix  glycyrrhizae  preparata  (Zhi  gancao)15  g;  Donkey-hide  gelatin  (e
jiao)15 g;  Radix  Ophiopogonis  (Mai  dong)  20  g;  Cassia  Twig(Gui  zhi)10  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)20  g;  Fructus  Cannabis  (Huo  maren)20  g;  Ginger(Sheng
jiang)5  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g
Ye et  al.27 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)18  g;  Donkey-hide  gelatin  (e
jiao)15 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig(Gui  zhi)10  g;
Codonopsis  pilosula  (Dang  shen)30  g;  the  dried  rhizome  of  rehmannia
(Sheng di)30  g;  Fructus  Cannabis  (Huo  maren)15  g;  Ginger  (Sheng
jiang)10  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g
Xing et  al.28 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)25  g;  Radix  Ophiopogonis  (Mai
dong) 10  g;  Cassia  Twig(Gui  zhi)9  g;  Codonopsis  pilosula  (Dang  shen)20  g;
the dried  rhizome  of  rehmannia  (Sheng  di)25  g;  Fructus  Cannabis  (Huo
maren)10  g;  Ginger  (Sheng  jiang)9  g;  Fructus  Ziziphi  Jujubae  (Da
zao)15  g;  Semen  Ziziphi  Spinosae  (Suan  zaoren)15  g
Zhang29 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;  Donkey-hide  gelatin  (e
jiao)10 g;  Radix  Ophiopogonis  (Mai  dong)  10  g;  Cassia  Twig  (Gui  zhi)10  g;
the dried  rhizome  of  rehmannia  (Sheng  di)10  g;  Fructus  Cannabis  (Huo
maren)10  g;  Ginger(Sheng  jiang)10  g;  Fructus  Ziziphi  Jujubae(Da
zao)10 g;  American  Ginseng  (Xi  yangshen)30  g;  Salvia  miltiorrhiza  (Dan
shen)30  g;  rhizoma  polygonati  (Huang  jing)20  g;  Panax  notoginseng  (San
qi)10 g;  Safﬂower(Hong  hua)10  g;  Ligusticum  wallichii  (Chuan  xiong)10  g;
rhizoma nardostachyos  (Gan  song)6  g;  Leech  (Shui  zhi)6  g
Luo30 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)12  g;  Donkey-hide  gelatin  (e
jiao)9 g;  Radix  Ophiopogonis  (Mai  dong)12  g;  Cassia  Twig(Gui  zhi)9  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)30  g;  Fructus  Cannabis  (Huo  maren)12  g;  Ginger  (Sheng
jiang)9  g;  Fructus  Ziziphi  Jujubae  (Da  zao)9  g
Chen31 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;  Donkey-hide  gelatin  (e
jiao)10 g;  Radix  Ophiopogonis  (Mai  dong)  30  g;  Cassia  Twig  (Gui  zhi)15  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)40  g;  Fructus  Cannabis  (Huo  maren)15  g;  Ginger  (Sheng
jiang)10  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g;  Radix  Bupleuri  (Chai
hu)15 g;  Tuber  Fleeceﬂower  Stem  (Ye  jiaoteng)30  g;  silk  tree  Albizzia
Bark  (He  huanpi)30  g
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Table  2  (Continued)
Study  ID  Formula  Composition  of  formula
Zhou  and  Zhang32 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)15  g;  Donkey-hide  gelatin  (e
jiao)10 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig  (Gui  zhi)10  g;
Codonopsis  pilosula  (Dang  shen)15  g;  Rehmannia  Glutinosa  (Shu  di)30  g;
Fructus Cannabis  (Huo  maren)15  g;  Ginger  (Sheng  jiang)10  g;  Fructus
Ziziphi Jujubae  (Da  zao)15  g
Niu et  al.33 Modiﬁed  ZGC  Decoction Radix  glycyrrhizae  preparata  (Zhi  gancao)18  g;  Donkey-hide  gelatin  (e
jiao)30 g;  Radix  Ophiopogonis  (Mai  dong)  30  g;  Cassia  Twig(Gui  zhi)30  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)15  g;  Fructus  Cannabis  (Huo  maren)15  g;  Schisandra  chinensis
(Wu weizi)15  g;  radix  paeoniae  rubrathe  (Chi  shao)15  g;  peach  kernel
(Tao ren)15  g;  Safﬂower(Hong  hua)15  g;  Codonopsis  pilosula  (Dang
shen)15  g
Li et  al.34 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;  Donkey-hide  gelatin  (e
jiao)15 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig  (Gui  zhi)15  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)15  g;  Fructus  Cannabis(Huo  maren)15  g;  Ginger  (Sheng
jiang)6  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g;  Astragalus
membranaceus  (Huang  qi)20  g;  Angelica  sinensis  (Dang  gui)10  g;  dens
draconis(Long  chi)30  g;  magnetite  (Ci  shi)30  g
Liang35 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;  Donkey-hide  gelatin  (e
jiao)15 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig  (Gui  zhi)15  g;
Codonopsis  pilosula  (Dang  shen)20  g;  the  dried  rhizome  of  rehmannia
(Sheng di)30  g;  Fructus  Cannabis  (Huo  maren)15  g;  Ginger  (Sheng
jiang)15  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g;  rhizoma  polygonati
(Huang  jing)15  g;  Panax  notoginseng  (San  qi)15  g;  rhizoma  nardostachyos
(Gan song)15  g
Bi and  Kang36 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;  Donkey-hide  gelatin  (e
jiao)15 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig  (Gui  zhi)15  g;
Codonopsis  pilosula  (Dang  shen)20  g;  the  dried  rhizome  of  rehmannia
(Sheng di)30  g;  Fructus  Cannabis  (Huo  maren)15  g;  Ginger  (Sheng
jiang)15  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g;  rhizoma  polygonati
(Huang  jing)15  g;  Panax  notoginseng  (San  qi)15  g;  rhizoma
nardostachyos(Gan  song)15  g;
Zhang et  al.37 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)12  g;  Donkey-hide  gelatin  (e
jiao)6 g;  Radix  Ophiopogonis  (Mai  dong)  10  g;  Cassia  Twig  (Gui  zhi)9  g;
Codonopsis  pilosula  (Dang  shen)6  g;  the  dried  rhizome  of  rehmannia
(Sheng di)30  g;  Fructus  Cannabis  (Huo  maren)10  g;  Ginger  (Sheng
jiang)9  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g
Wang38 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)15  g;  Donkey-hide  gelatin  (e
jiao)6 g;  Cassia  Twig  (Gui  zhi)6  g;  15  g;  Fructus  Cannabis  (Huo
maren)10  g;  Ginger  (Sheng  jiang)6  g;  Fructus  Ziziphi  Jujubae(Da
zao)10  g;  Rehmannia  Glutinosa  (Shu  di)10  g;  Schisandra  chinensis  (Wu
weizi)6 g;  Codonopsis  pilosula  (Dang  shen)20  g;  radix  sophorae
ﬂavescentis  (Ku  shen)20  g
Guo39 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)15  g;  Donkey-hide  gelatin  (e
jiao)6 g;  Radix  Ophiopogonis  (Mai  dong)  10  g;  Cassia  Twig  (Gui  zhi)9  g;
Codonopsis  pilosula  (Dang  shen)15  g;  the  dried  rhizome  of  rehmannia
(Sheng di)20  g;  Fructus  Cannabis  (Huo  maren)10  g;  Ginger  (Sheng
jiang)9  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g
Fan and  Guo40 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)12  g;  Donkey-hide  gelatin  (e
jiao)6 g;  Radix  Ophiopogonis  (Mai  dong)  12  g;  Cassia  Twig  (Gui  zhi)9  g;
Codonopsis  pilosula(Dang  shen)6  g;  the  dried  rhizome  of  rehmannia
(Sheng  di)48  g;  Fructus  Cannabis  (Huo  maren)12  g;  Ginger(Sheng
jiang)9  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g
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Table  2  (Continued)
Study  ID  Formula  Composition  of  formula
Li  and  Zhou41 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)30  g;  Donkey-hide  gelatin  (e
jiao)10 g;  Radix  Ophiopogonis  (Mai  dong)  10  g;  Cassia  Twig  (Gui  zhi)9  g;
Codonopsis  pilosula  (Dang  shen)20  g;  the  dried  rhizome  of  rehmannia
(Sheng di)15  g;  Ginger(Sheng  jiang)9  g;  Fructus  Ziziphi  Jujubae(Da
zao)10 g;  Semen  Ziziphi  Spinosae  (Suan  zaoren)10  g;  radix  sophorae
ﬂavescentis(Ku  shen)15  g;  Salvia  miltiorrhiza  (Dan  shen)30  g;  Ligusticum
wallichii  (Chuan  xiong)15  g;  radix  paeoniae  rubrathe  (Chi  shao)15  g;
Wang and  Zhao42 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao);  Donkey-hide  gelatin  (e  jiao);
Radix Ophiopogonis  (Mai  dong);  Cassia  Twig  (Gui  zhi);  Codonopsis
pilosula(Dang  shen);  the  dried  rhizome  of  rehmannia  (Sheng  di);  Fructus
Cannabis  (Huo  maren);  Ginger  (Sheng  jiang);  Fructus  Ziziphi  Jujubae  (Da
zao)
Ning43 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)20  g;  Donkey-hide  gelatin  (e
jiao)20 g;  Radix  Ophiopogonis  (Mai  dong)  15  g;  Cassia  Twig(Gui  zhi)12  g;
Codonopsis  pilosula  (Dang  shen)10  g;  the  dried  rhizome  of  rehmannia
(Sheng di)20  g;  Fructus  Cannabis  (Huo  maren)15  g;  Ginger(Sheng
jiang)5  g;  Fructus  Ziziphi  Jujubae  (Da  zao)10  g;  Salvia  miltiorrhiza  (Dan
shen)30  g;  tortoise  plastron  (Gui  ban)  20  g
Wang44 ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)60  g;  Donkey-hide  gelatin  (e
jiao)15 g;  Radix  Ophiopogonis  (Mai  dong)  30  g;  Cassia  Twig  (Gui  zhi)30  g;
Codonopsis  pilosula  (Dang  shen)30  g;  the  dried  rhizome  of  rehmannia
(Sheng di)90  g;  Fructus  Cannabis  (Huo  maren)30  g;  Ginger  (Sheng
jiang)30  g;  Fructus  Ziziphi  Jujubae  (Da  zao)20  g
Wang45 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)10  g;  Radix  Ophiopogonis  (Mai
dong) 10  g;  Cassia  Twig  (Gui  zhi)10  g;  Codonopsis  pilosula  (Dang
shen)10  g;  Fructus  Cannabis  (Huo  maren)10  g;  Ginger  (Sheng  jiang)5  g;
Rhizoma  Dioscoreae  (Shan  yao)15  g;  Pericarpium  trichosanthis  (Gua
loupi)10 g;  Schisandra  chinensis  (Wu  weizi)10  g;  rhizoma  nardostachyos
(Gan song)10  g;
Yuan and  Wang46 Modiﬁed  ZGC  Decoction  Radix  glycyrrhizae  preparata  (Zhi  gancao)15  g;  Donkey-hide  gelatin  (e
jiao)12 g;  Radix  Ophiopogonis  (Mai  dong)  12  g;  Cassia  Twig  (Gui  zhi)9  g;
Codonopsis  pilosula  (Dang  shen)10  g;  the  dried  rhizome  of  rehmannia
(Sheng di)12  g;  Fructus  Cannabis  (Huo  maren)10  g;  Ginger  (Sheng
jiang)6  g;  Fructus  Ziziphi  Jujubae  (Da  zao)15  g;  dens  draconis  (Long
chi)30  g;  oyster  (Mu  li)  30  g
b
c
f
o
s
i
i
a
t
e
E
W
h13  trials34—46 compared  the  combination  of  ZGC  Decoction
and  anti-arrhythmic  drugs  with  anti-arrhythmic  drugs.  The
total  treatment  duration  ranged  from  3  to  12  weeks.  The
dosage  of  ZGC  Decoction  was  one  dose  twice  a  day.  All  of
the  25  trials  used  total  effect  for  PVCs  as  the  main  outcome
measure  and  5  trials27,35,39—41 reported  number  of  ventricular
premature  beat  as  the  primary  outcome.  13  trials  reported
adverse  events.23,26,28—30,33,37,39—41,43,45,46 The  characteristics
of  25  trials  were  summarized  in  Table  1  and  ZGC’s  dosages
and  compositions  are  listed  in  Table  2.
Methodological  quality  of  the  included  trials
Figs.  2  and  3  present  the  methodological  quality  of  the  25
studies  reviewed.  Only  5  studies28,39,40 stated  the  method
of  the  sequence  generation  with  random  number  table  and
drawing,23,31 while  no  speciﬁc  information  was  provided  in
the  other  trials  to  judge  whether  or  not  it  was  conducted
properly.  None  of  them  described  allocation  concealment,
i
t
Z
alinding  of  participants  and  personnel,  and  blinding  of  out-
ome  assessment.  Only  one  trial28 reported  information  on
ollow-up  and  two  trials23,26 had  reported  dropout  with-
ut  explaining  their  reasons.  There  also  were  unclear  on
elective  reporting  outcome  in  the  studies  because  of  the
naccessibility  to  the  study  protocol.  Moreover,  none  of  the
ncluded  studies  used  intention-to-treat  analysis  and  no  tri-
ls  provided  a  pretrial  estimation  of  sample  size.  In  a  word,
he  methodological  quality  of  most  included  trials  was  gen-
rally  ‘‘poor’’.
ffects  of  the  interventions
e  used  subgroup  analysis  with  consideration  of  clinical
eterogeneity  across  the  studies.  25  studies  were  divided
nto  two  groups:  one  evaluated  the  effects  of  ZGC  Decoc-
ion  versus  anti-arrhythmic  drugs,  the  other  compared
GC  Decoction  plus  any  anti-arrhythmic  drugs  versus  anti-
rrhythmic  drugs  alone.  Descriptions  and  interpretations  of
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otal  effect  for  PVCs  and  numbers  of  ventricular  premature
eat  in  all  studies  followed  the  rules  prescribed  in  the  Clini-
al  research  guideline  of  medicine  for  cardiovascular  system
y  Ministry  of  Public  Health  (1998).otal  effect  for  PVCs
ll  the  25  trials22—46 reported  the  total  effects  for  PVCs.
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Figure  2  Risk  of  bias  summary:  review  authors’  judgemenW.  Liu  et  al.
nti-arrhythmic  drugs.  A  change  in  the  total  effect  was
eported  in  all  the  included  RCTs.  The  trials  did  show  signiﬁ-
antly  heterogeneity  in  the  trial  results,  chi-square  =  42.51,
f  =  11,  (P  <  0.0001);  I2 =  74%.  Thus,  random-effects  model
hould  be  used  for  statistical  analysis.  The  meta-analysis
howed  there  are  signiﬁcant  beneﬁcial  effects  on  the  ZGC
ecoction  group  compare  to  anti-arrhythmic  drugs  using
lone  (RR:  1.22,  95%  CI:  1.08—1.37;  P  =  0.0009)  (Fig.  4).  2
ndependent  trials22,26 did  show  better  effect  stratiﬁed  class
I  according  to  the  Lown  classiﬁcation,  One  trial22 discovered
he  better  effect  (RR:  1.27,  95%  CI:  1.01—1.59;  P  =  0.04).  The
ther  trial26 reported  that  ZGC  Decoction  is  superior  to  anti-
rrhythmic  drugs  (RR:  1.21,  95%  CI:  1.06—1.39;  P  =  0.005).
owever,  there  were  statistically  signiﬁcant  differences  on
he  ZGC  Decoction  group  to  anti-arrhythmic  drugs  using
lone  in  one  trial32 stratiﬁed  class  II  to  IV  according  to  the
own  classiﬁcation  (RR:  1.21,  95%  CI:  1.06—1.39;  P  =  0.002).
roup  II.  ZGC  Decoction  plus  anti-arrhythmic  drugs  versus
nti-arrhythmic  drugs.  These  13  trials34—46 compared  the
ombination  of  ZGC  Decoction  plus  anti-arrhythmic  drugs
ith  anti-arrhythmic  drugs.  The  effect  estimates  were
hown  in  the  Fig.  5. Trial  results  for  the  thirteen  indepen-
ent  trials  were  homogeneous,  chi-square  =  6.26,  df  =  12,
P  =  0.90);  I2 =  0%,  requiring  the  use  of  the  ﬁxed  effects
odel  for  statistical  analysis.  The  effective  frequency  num-
er  after  ZGC  Decoction  combined  with  anti-arrhythmic
rugs  was  more  than  anti-arrhythmic  drug  treatment.
he  meta-analysis  demonstrated  a  signiﬁcant  difference
etween  the  two  groups.  (RR:  1.30,  95%  CI:  1.22—1.38;
 <  0.00001).  A  total  of  two  trials37,38 evaluated  the  ther-
peutic  effect  of  ZGC  Decoction  in  combination  with
nti-arrhythmic  drug  in  patients  with  class  II  PVCs  compared
ith  anti-arrhythmic  drug.  One  trial37 discovered  the  bet-
er  effect  on  total  effect  (RR:  1.33,  95%  CI:  1.08—1.64;
 =  0.007).  The  other  trial38 reported  that  ZGC  Decoction
s  superior  to  anti-arrhythmic  drugs  (RR:  1.28,  95%  CI:
39.04—1.57;  P  =  0.02).  Guo  ZhiYu conducted  an  RCT  to  assess
he  effectiveness  of  ZGC  Decoction  on  persons  with  PVCs
tratiﬁed  class  II  to  IV  according  to  the  Lown  classiﬁcation.
t  the  end  of  the  trial,  the  experimental  group  signiﬁcantly
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mproved  total  effect  compared  with  the  control  group  (RR:
.50,  95%  CI:  1.14—1.98;  P  =  0.004)
umber  of  ventricular  premature  beats
 total  of  4  trials35,39—41 reported  the  effect  of  ZGC  Decoc-
ion  in  combination  with  anti-arrhythmic  drugs  compared
ith  anti-arrhythmic  drugs  in  patients  with  PVCs.  The
 independent  trials  did  show  signiﬁcantly  heterogeneity
n  the  trial  results,  chi-square  =  10.92,  (P  =  0.01);  I2 =  73%.
hus,  random-effects  model  should  be  used  for  statistical
nalysis.  The  meta-analysis  showed  there  are  signiﬁcant
eneﬁcial  effects  on  the  combination  group  compare  to  anti-
rrhythmic  drugs  using  alone  (MD:  −6.66  [−12.94,  −0.37];
 =  0.04)  (Fig.  6).
dverse  effect
 total  of  13  trials  described  adverse
vents.23,26,28—30,33,37,39—41,43,45,46 Among  them,  one  trial26
eported  2  cases  long  QT  (2.82%)  and  1  case  liver  function
amage  (1.41%)  in  the  western  medicine  group.  One  trial28
eported  adverse  effect  including  2  cases  of  loss  of  appetite
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utcome total  effect.nd  abdominal  distension  (4.55%)  in  ZGC  Decoction  and  1
ase  arrhythmia  (2.17),  1  case  dizziness  (2.17),  3  cases  loss
f  appetite,  nausea  (6.52%)  in  the  controlled  group.  One
rial30 reported  long  QT  and  one  trial33 described  4  cases
astro-intestinal  symptoms  (11.11%)  and  1  case  I atrioven-
ricular  block  (2.78%)  in  the  western  medicine  group.  One
tudy41 represented  11  cases  gastro-intestinal  symptoms
7.33%)  and  9  cases  dizziness  (6.00%)  in  the  combination  of
hinese  traditional  and  Western  medicine  group  and  6  cases
astro-intestinal  symptoms  (9.68%)  and  4  cases  dizziness
6.45%)  in  the  anti-arrhythmic  drugs  group.  One  trial43
eported  8  cases  nausea,  hiccups,  abdominal  pain  (17.8%)
n  the  anti-arrhythmic  drugs  group.  One  trial46 described
 case  chest  distress,  palpitations  in  ZGC  Decoction  in
ombination  with  anti-arrhythmic  drugs  group.  In  addition,
o  adverse  events  were  found  in  6  trials.23,29,37,39,40,45
ublication  biashe  forest  plot  of  comparison  of  ZGC  Decoction  combined
ith  anti-arrhythmic  drugs  versus  anti-arrhythmic  drugs  for
he  outcome  total  effect  was  shown  in  the  Fig.  7.
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Discussion
Premature  Ventricular  Contractions  (PVCs)  are  frequently
observed  on  standard  12-lead  electrocardiograms  in  healthy
people.47,48 The  signiﬁcance  of  PVCs  in  subjects  with  exist-
ing  coronary  heart  disease  is  relatively  well  understood;
for  instance,  The  Framingham  Heart  Study  demonstrated
that  men  without  coronary  heart  disease  who  had  com-
plex  or  frequent  ventricular  arrhythmias  were  at  increased
risk  for  all-cause  mortality  (relative  risk  2.30)  and  the
occurrence  of  myocardial  infarction  or  death  from  coro-
nary  heart  disease  (relative  risk  2.12).49 Clinical  course
of  PVCs  varies  from  asymptomatic  to  the  miscellaneous
symptoms,  range  from  palpitations  only  to  more  severe
manifestations  as  syncope,  which  cause  abnormal  work
and  life  in  patients,  and  even  endanger  the  safety  of  life
seriously.
ZGC  Decoction  is  a  classic  herbal  formula  that  may  have
protective  effect  in  patients  with  palpitations  and  has  been
used  for  cardiovascular  diseases  for  hundreds  of  years  in
China.  Recently,  with  the  growing  and  sustained  interest
in  the  beneﬁts  of  Traditional  Chinese  herbs  and  integrative
medicine  (IM),  ZGC  Decoction  alone  or  combined  with  anti-
arrhythmic  drugs  have  been  widely  used  as  an  alternative
and  effective  method  for  PVCs  in  China.  Meanwhile,  there
have  been  a  large  number  of  fundamental  research  and  clin-
ical  trials  of  ZGC  Decoction  on  PVCs  and  RCTs.  The  studies
in  this  review  demonstrated  that  ZGC  Decoction  may  have
beneﬁcial  effects  for  a  variety  of  populations  on  PVCs.  The
result  showed  ZGC  Decoction  as  an  adjunctive  treatment
to  anti-arrhythmic  drugs  signiﬁcantly  could  improve  total
effect  for  PVCs  and  decrease  the  number  of  ventricular  pre-
mature  beat  in  patients  with  PVCs.  However,  the  deﬁnite
conclusion  cannot  be  drawn  from  this  paper  because  of  the
following  limitations.
Firstly,  we  still  cannot  make  ﬁrm  conclusions  due  to  poor
methodological  quality,  although  all  25  RCTs  claimed  that
the  positive  effect  of  ZGC  Decoction  alone  or  combined  with
anti-arrhythmic  drugs  was  better  than  anti-arrhythmic  drugs
alone.  The  following  problems  in  reporting  contribute  to  the
limited  methodological  quality  of  most  included  trials:  (1)
Random  sequence  generation  and  allocation  concealment:
all  trials  reported  randomization,  but  only  5  studies28,39,40
stated  the  method  of  the  sequence  generation  with  ran-
dom  number  table  and  drawing.23,31 In  addition,  all  the  trials
did  not  describe  allocation  concealment  in  details.  A  num-
ber  of  trials22—26,29—31,35,38,39,43,45 only  have  one  author,  which
is  impossible  for  a  RCT  to  be  done  properly  in  terms  of
randomization  procedure  and  the  allocation  concealment.
(2)  Blinding:  none  of  them  described  blinding  of  partici-
pants  and  personnel  and  blinding  of  outcome  assessment.
It  directly  led  to  performance  bias  and  detection  bias  due
to  patients  and  researchers  being  aware  of  the  therapeu-
tic  interventions  for  the  subjective  outcome  measures.  (3)
Withdrawal/dropout:  only  one  trial28 reported  information
on  follow-up,  two  trials23,26 had  reported  dropout  and  one26
with  the  detailed  reasons.  (4)  Selective  reporting:  they
failed  to  provide  enough  information  for  selective  reporting,
so  selective  reporting  bias  might  exist  in  this  conclusion.
Moreover,  all  the  included  trials  were  not  multicenter,  large
scale  RCTs.
i
w
s113
Secondly,  heterogeneity  is  worthy  of  being  paid  atten-
ion  to.  All  the  trials  used  the  improvement  of  total  effect
or  PVCs  in  the  ZGC  Decoction  relative  to  anti-arrhythmic
rugs  were  not  homogeneous.  And  not  only  that,  the  4
ndependent  trials  using  ZGC  Decoction  combined  with
nti-arrhythmic  drugs  compared  with  anti-arrhythmic  drugs
lone  did  show  signiﬁcantly  heterogeneity  in  the  results  of
umber  of  ventricular  premature  beat.  The  main  source
f  the  heterogeneity  may  have  several  aspects.  One  of
he  major  limitations  was  the  clinical  and  methodological
ource.  Because  of  different  diagnosis  standards  can  make  a
ig  difference.  Several  trials  study  PVCs  patients  with  struc-
ural  heart  disease.  5  trials27,29,39—41 assessed  ZGC  Decoction
or  treatment  of  coronary  heart  disease  with  frequent
entricular  premature  contractions;  one  trial24 reported
atients  with  functional  PVCs,  and  11  trials22—28,38,43—45
nrolled  patients  with  frequent  premature  ventricular  com-
lexes.  In  addition,  25  trials  speciﬁed  5  diagnostic  criteria
number  of  premature  ventricular  beat  more  than  60/h,
0/h,  5/min  or  300/h).  Beyond  that,  the  durations  of
reatment  were  various  (ranged  from  3  to  12  weeks),  and
eported  various  kinds  of  anti-arrhythmic  drugs  were  diverse
n  included  trials.  6  different  anti-arrhythmic  drugs  were
nvestigated  in  the  25  trials.  Classes  I  B  anti-arrhythmic
rugs  Mexiletine  Hydrochloride  Tablets  (150  mg,  tid)  were
ut  into  use  by  6  studies;27,32,38—40,43 8  trials  shown  two
lasses  I c  anti-arrhythmic  drugs,  including  Moracizine28 and
ropafenone23,29,33—36,41 with  different  dose  (75—200  mg)  and
requency  (bid  or  tid).  7  cases22,25—27,30,43,44 used  a  class  III
nti-arrhythmic  agent  Amiodarone  (200  mg,  tid,  p.o.);  The
est  studies  selected24,31,32,37,45,46 the  medical  therapy  of
eta  blockers.  As  a  result,  it  is  difﬁcult  to  undertake  sub-
roup  analyses  to  explore  speciﬁc  factors  that  may  have  an
mpact  on  the  effects  of  the  treatment  regimen.
Thirdly,  a  total  of  13  trials23,26,28—30,33,37,39—41,43,45,46 of  24
rials  did  mention  adverse  effect.  Only  one  trial28 reported
dverse  effect  in  ZGC  Decoction  group  including  loss  of
ppetite  and  abdominal  distension.  Even  for  the  trials  that
eported  adverse  events,  their  report  was  very  brief,  pro-
iding  limited  information.  Two  trials41,46 recorded  some
peciﬁc  symptoms  in  the  group  of  ZGC  Decoction  in  combi-
ation  with  anti-arrhythmic  drugs,  and  six  cases26,28,30,33,41,43
entioned  side  effects  in  anti-arrhythmic  drugs  group,
ncluding  nausea,  loss  of  appetite,  hiccups,  abdominal  pain,
eadache,  dizziness,  constipation,  I  atrioventricular  block,
ong  Q-T  and  so  on.  These  side  effects  may  be  related  to
he  adverse  effect  of  anti-arrhythmic  drugs.  In  addition,  no
dverse  events  were  found  in  6  trials.23,29,37,39,40,45 There-
ore,  a  conclusion  about  the  safety  of  ZGC  Decoction  cannot
e  made  clearly.  Only  one  trail28 reported  information  on
ollow-up,  but  not  mentioned  the  details.  In  order  to  proper
ssess  the  safety  of  ZGC  Decoction,  large-scale  clinical  trials
ith  long-term  follow-up  are  required.
Last  but  not  least,  funnel  plot  (Fig.  7)  indicated  that
ublication  and  other  biases  may  play  an  important  role,
ince  all  of  the  trials  were  small  size  with  no  ‘negative’
nd  conducted  in  China.  We  found  that  the  quality  of  the
ethodology  of  the  RCTs  included  in  this  systematic  reviews  generally  low,  so  the  evidences  need  to  be  interpreted
ith  caution.  In  addition,  we  only  identiﬁed  unpublished
tudies  from  conference  paper  or  academic  thesis,  and
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114  
egative  trials  might  not  be  reported  and  induced  publica-
ion  bias.
onclusion
his  is  the  ﬁrst  meta-analysis  of  randomized,  controlled
rials  to  assess  the  efﬁcacy  and  safety  of  ZGC  Decoc-
ion  in  patient  with  PVCs.  In  our  meta-analysis,  patients
eceiving  ZGC  Decoction  adjunct  therapy  alone  or  combined
ith  anti-arrhythmic  drugs  exhibit  signiﬁcant  improvement
n  their  total  effects  and  number  of  ventricular  prema-
ure  beats.  However,  methodological  robust  trials  are  still
eeded  to  further  evaluate  this  therapy  due  to  the  gen-
rally  low  methodological  quality  of  the  included  studies.
he  included  trials  were  generally  of  small  sample  size.
s  a  result,  a  deﬁnite  conclusion  on  efﬁcacy  and  adverse
vents  associated  with  ZGC  Decoction  cannot  be  drawn  from
his  review.  Therefore,  there  is  a  need  for  additional  RCTs
hat  emphasize  not  only  well-designed,  randomized,  double-
lind,  placebo-controlled  trials,  but  also  reported  in  detail
ccording  to  CONSORT50 or  CONSORT  for  TCM.
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